Sienna Clinic Medycyna Specjalistyczna Sp. z o.o.

The team at Sienna Clinic Medycyna Specjalistyczna Sp. z o.o. focuses on cardiovascular diseases, primarily investigating innovative anticoagulant approaches for Coronary artery disease. Current studies aim to assess the safety, tolerability and pharmacodynamic impact of novel agents that target Factor XI, with the goal of improving clot‑prevention strategies.

• Factor XI inhibition
• Injection‑based therapy evaluation
• Dose‑response assessment
• Coagulation activity monitoring

Findings from these trials may shape future treatment guidelines for patients with coronary artery disease across Europe.

Research at Sienna Clinic Medycyna Specjalistyczna Sp. z o.o. also targets Venous thromboembolism, especially in individuals with a history of clotting events or cancer‑related high risk. The investigations evaluate the pharmacodynamic effects of emerging therapies, seeking to enhance safety and effectiveness of long‑term anticoagulation.

• Blood‑clot prevention in high‑risk groups
• Vortosiran therapeutic assessment
• Post‑thrombotic management strategies
• Risk stratification and monitoring

Results are expected to contribute to better management protocols for venous thromboembolism patients worldwide.